Antibody responses to pneumococcal and hemophilus vaccinations in splenectomized patients with hematological malignancies or trauma

Wiener Klinische Wochenschrift

Volumn 119, Issue 7-8, 2007, Pages 228-234

  Eigenberger, Karin ^a   Sillaber, Christian ^a   Greitbauer, Manfred ^a   Herkner, Harald ^a   Wolf, Hermann ^b   Graninger, Wolfgang ^a   Gattringer, Rainer ^a   Burgmann, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Immunology Outpatient Clinic   (Austria)

Author keywords

23 valent pneumococcal polysaccharide vaccination; Haemophilus influenzae type b vaccination; Immune response; Immunosuppression; Splenectomy

Indexed keywords

ACT HIB; HAEMOPHILUS INFLUENZAE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HAEMOPHILUS INFLUENZAE TYPE B; HEMATOLOGIC MALIGNANCY; HUMAN; OUTPATIENT; PROSPECTIVE STUDY; SINGLE DRUG DOSE; SPLENECTOMY; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADULT; AGED; ANTIBODIES; BACTERIAL VACCINES; FEMALE; HAEMOPHILUS INFECTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; POLYSACCHARIDES, BACTERIAL; RISK ASSESSMENT; RISK FACTORS; SPLENECTOMY; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 34250185007     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0752-5     Document Type: Article

References (25)

1. Schwartz PE, Sterioff S, Mucha P, Melton LJ, Offord KP (1982) Postsplenectomy sepsis and mortality in adults. JAMA 248: 2279-2283
2. Berghold C, Berghold A, Fulop G, Heuberger S, Strauss R, Zenz W (2006) Invasive meningococcal disease in Austria 2002: assessment of completeness of notification by comparison of two independent data sources. Wien Klin Wochenschr 118 (1-2): 31-35
3. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR (1993) Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270: 1826-1831
4. Schafer H, Ewing S (2000) Pneumonia in the elderly - what makes the difference? Wien Klin Wochenschr 112 (13): 566-575
5. Konradsen HB (1996) Humoral immune response to pneumococcal vaccination. Prevention of infections with Streptococcus pneumoniae by immunization. APMIS [Suppl] 60: 1-28
6. Bruyn GA, van Furth R (1991) Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations. Eur J Clin Microbiol Infect Dis 10: 897-910
7. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325: 1453-1460
8. Pirofski LA, Casadevall A (1998) Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 11: 1-26
9. Hartkamp A, Mulder AHL, Rijkers GT, van Velzen-Blad H, Biesma DH (2001) Antibody response to pneumococcal and haemophilus vaccination in patients with B-cell chronic lymphocytic leukaemia. Vaccine 19: 1671-1677
10. Petrasch S, Kuhnemund O, Reinacher A, Uppenkamp M, Reinert R, Schmiegel W, Lutticken R, Brittinger G (1997) Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines. Clin Diagn Lab Immunol 4: 635-638
11. Frederiksen B, Specht L, Henrichsen J, Pedersen FK, Pedersen-Bjergaard J (1989) Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease. Eur J Haematol 43: 45-49
12. Lazarus HM, Lederman M, Lubin A, Herzig RH, Schiffman G, Jones P, Wine A, Rodman HM (1980) Pneumococcal vaccination: the response of patients with multiple myeloma. Am J Med 69: 419-423
13. Ullmann AJ, Karthaus M, Cornely A (2004) Vaccination of the immunocompromised host. Wien Med Wochenschr 154 (9-10): 218-225
14. Spoulou V, Victoratos P, Ioannidis JPA, Grafakos S (2000) Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J Infect Dis 182: 965-969
15. Waghorn DJ (2001) Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol 54: 214-218
16. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M (2001) Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19: 4780-4790
17. Caplan ES, Boltansky H, Snyder MJ, Rooney J, Hoyt NJ, Schiffman G, Cowley RA (1983) Response of traumatized splenectomized patients to immediate vaccination with polyvalent pneumococcal vaccine. J Trauma 23: 801-805
18. Shatz DV, Romero-Steiner S, Elie CM, Holder PF, Carlone GM (2002) Antibody responses in postsplenectomy trauma patients receiving the 23-valent pneumococcal polysaccharide vaccine at 14 versus 28 days postoperatively. J Trauma 53: 1037-1042
19. Huo Z, Miles J, Harris T, Riches P (2002) Effect of Pneumovax II vaccination in high risk individuals on specific antibody and opsonic capacity against specific and non-specific antigen. Vaccine 20: 3532-3534
20. Weintrub PS, Schiffman G, Addiego JE Jr, Matthay KK, Vichinsky E, Johnson R, Lubin B, Mentzer WC, Ammann AJ (1984) Long-term follow-up and booster immunization with polyvalent pneumococcal polysaccharide in patients with sickle cell anemia. J Pediatr 105: 261-263
21. Hinweise zu Impfungen für Patienten mit Immundefizienz. (2005) Epidemiologisches Bulletin 10: 1-12
22. Zielen S, Bühring I, Strnad N, Reichenbach J, Hofmann D (2000) Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to 23-valent pneumococcal vaccine. Infect Immun 68: 1435-1440
23. Chan CY, Molrine DC, George S, Tarbell NJ, Mauch P, Diller L, Shamberger RC, Phillips NR, Goorin A, Ambrosino DM (1996) Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 173: 256-258
24. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg K, Schamberger RC, Anderson EL, Phillips NR, Kinsella K, Ambrosino DM (1995) Antibody response to polysaccaride and polysaccaride-conjugate vaccine after treatment of Hodgkin disease. Ann Intern Med 123: 828-834
25. Stoehr GA, Rose MA, Eber SW, Heidemann K, Schubert R, Zielen S (2005) Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. BJH 132: 788-790